Article Sidebar

PDF
Date Published: 01/06/2023
Abstract Views: 715
Views PDF: 165
DOI: https://doi.org/10.51298/vmj.v526i2.5495
Issue
Vol. 526 No. 2 (2023)
Section
Các bài báo
How to Cite
Trần, T. ., Phạm , T. Q. ., & Nguyễn, V. H. . (2023). EVALUATION OF THE EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN REGIMENS IN ADVANCED PANCREATIC CANCER PATIENTS AT K HOSPITAL. Vietnam Medical Journal, 526(2). https://doi.org/10.51298/vmj.v526i2.5495

EVALUATION OF THE EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN REGIMENS IN ADVANCED PANCREATIC CANCER PATIENTS AT K HOSPITAL

Thắng Trần1,, Thị Quế Phạm 1, Văn Huy Nguyễn1
1 k hospital

Main Article Content

Abstract

Objective: Evaluation of the efficacy and safety of Gemcitabine plus cisplatin regimens in advanced pancreatic cancer patients at K Hospital. Methods: This retrospective descriptive study analyzed. 32 advanced pancreatic cancer patients were treated with Gemcitabine plus cisplatin regimens. Overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) were analyzed, and some factors predicting the effectiveness of chemotherapy regimens were identified. Results: From January 2020 to November 2018, 32 patients were enrolled in the trial. Response rate was 21.9%. Disease control rate was 40.7%. The median PFS and OS were 8.2 months and 10.9 months, respectively. The rate of hematologic and non-hematologic adverse effects was low, mostly grade 1 and 2 including anemia, leukopenia, Thrombocytopenia. These percentages were 78.2 %, 43.8%, 62.5%, respectively. Conclusion: First line  gemcitabine plus cisplatin regimens for advanced pancreatic cancer patients was a safe and effective modality.

Article Details

Keywords

advanced pancreatic cancer, gem-cis regimen

References

1. Nguyễn Bá Đức, Trần Văn Thuấn, Nguyễn Tuyết Mai. Ung Thư Tụy. Điều Trị Nội Khoa Bệnh Ung Thư. 2010, Nhà Xuất Bản y Học, Việt Nam, 189–199.
2. Ferlay J., Soerjomataram I., Dikshit R., et al. (2015). Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. Int J Cancer, 136(5), E359-386.
3. Siegel R.L., Miller K.D., and Jemal A. (2016). Cancer Statistics, 2016. CA Cancer J Clin, 66(1), 7–30.
4. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24(24):3946-3952. doi:10.1200/JCO.2005.05.1490
5. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/ j.ejca.2008.10.026.
6. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed September 20, 2020. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#c tc_50.
7. Ung thư tụy. In: Điều Trị Nội Khoa Bệnh Ung Thư. 2010th ed. Nhà xuất bản y học; :189-199.
8. Tempero MA, Cha C, Hawkins WG, Obando J. NCCN Guidelines Index Table of Contents Discussion. Published online 2018:159.